Endovastec(SH:688016) Sou Hu Cai Jing·2026-01-06 00:31Core Viewpoint - The stock of Xinmai Medical (688016) has shown a positive performance with a closing price of 95.84 yuan, reflecting a 4.56% increase as of January 5, 2026, indicating strong market interest and potential growth in the medical device sector [1]. Financial Performance - Xinmai Medical reported a total revenue of 1.015 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 4.66% [4]. - The net profit attributable to shareholders for the same period was 429 million yuan, showing a decline of 22.46% year-on-year [4]. - The company achieved a gross margin of 70.4%, significantly higher than the industry average of 51.02% [4]. Market Position - Xinmai Medical's total market capitalization stands at 11.813 billion yuan, which is above the industry average of 11.28 billion yuan [4]. - The company ranks 16th in net profit within the medical device industry, with a net profit of 429 million yuan, compared to the industry average of 210 million yuan [4]. - The price-to-earnings (P/E) ratio for Xinmai Medical is 20.65, which is considerably lower than the industry average of 81.51, indicating a potentially undervalued stock [4]. Investment Sentiment - Over the past 90 days, 7 institutions have rated Xinmai Medical, with 6 giving a "buy" rating and 1 an "accumulate" rating, suggesting strong institutional confidence in the stock [5]. - The average target price set by institutions for Xinmai Medical is 136.03 yuan, indicating a potential upside from the current trading price [5]. Trading Activity - On January 5, 2026, the net inflow of main funds was 8.6933 million yuan, accounting for 3.74% of the total trading volume, while retail investors showed a net inflow of only 42,500 yuan [1]. - The financing data indicates a net purchase of 2.943 million yuan on the same day, reflecting positive investor sentiment towards the stock [2].